In short
Clinical trials are investigating Azd5462 in people with chronic heart failure. These studies are looking at whether different doses are safe and effective, especially in stable patients. The main goal is to see how heart structure and function change during treatment.
Key points
- Azd5462 is being studied in clinical trials for chronic heart failure. The available trial is a Phase 2, randomised, placebo controlled, double blind, multi-centre, dose-ranging study. It includes stable patients with chronic heart failure. The trial looked at different doses and compared them with placebo. The main outcome was change in echocardiographic measurements from baseline to Week 25. The study is completed and enrolled 372 participants.
Clinical trial overview
The available study of Azd5462 is a Phase 2 trial in people with chronic heart failure. It was designed to evaluate the effect and dose response of Azd5462 after 24 weeks of treatment in participants with heart failure.
The trial was completed and enrolled 372 participants.
Study design and what it means
This study was a randomised, placebo controlled, double blind, multi-centre, dose-ranging study.
Randomised means participants were assigned by chance to a study group. Placebo controlled means one group received a look-alike treatment with no active study drug for comparison. Double blind means neither the participants nor the study staff knew who received Azd5462 or placebo during the study.
Multi-centre means the trial was done at more than one study site, which can help include a wider range of participants. Dose-ranging means the study compared different doses to see how response may change with dose.
Who could participate
The trial focused on stable patients with chronic heart failure. Stable patients are people whose heart failure is not suddenly worsening.
The source data does not list more detailed entry rules, so the main known target group is adults with chronic heart failure who were stable enough to join a study like this.
What was measured in the study
The primary outcome was the change in echocardiographic measurements from baseline to Week 25. Primary outcome means the main result the researchers planned to measure.
Echocardiographic measurements are heart measurements taken with echocardiography, an ultrasound test that shows the heart's structure and function. Baseline means the starting point before treatment begins, and Week 25 is the study visit 25 weeks later.
The brief summary says the trial was meant to evaluate the effect and dose response of Azd5462 after 24 weeks of treatment in participants with heart failure.
Trial status and size
The trial status is listed as Completed. A total of 372 participants were enrolled.
The trial used oral Azd5462 and a matching placebo tablet supplied in the same pack as the active treatment.